A randomized, double-blind, placebo-controlled, dose-ranging, study to evaluate the efficacy, safety and tolerability of single doses of BCX7353 as an acute attack treatment in subjects with hereditary angioedema

Trial Profile

A randomized, double-blind, placebo-controlled, dose-ranging, study to evaluate the efficacy, safety and tolerability of single doses of BCX7353 as an acute attack treatment in subjects with hereditary angioedema

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs BCX 7353 (Primary)
  • Indications Hereditary angioedema
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ZENITH-1
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 27 Feb 2018 According to a BioCryst Pharmaceuticals media release, enrollment in the 750 mg cohort of the study has been completed and the 500 mg cohort is currently enrolling. Company expects top-line results from the first cohort in the second half of 2018.
    • 03 Aug 2017 Planned End Date changed from 10 May 2018 to 1 Nov 2018.
    • 02 Aug 2017 According to a BioCryst Pharmaceuticals media release, the first subject has been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top